MD Anderson Cancer Center Now Enrolling Patients in Rafael Pharmaceuticals’ Phase 2 Clinical Trial of CPI-613® (devimistat) for Relapsed or Refractory Burkitt’s Lymphoma/Leukemia

NEXT STORY
Vaxil Announces Audited Annual Results and Provides Business Update
PREV STORY
Sarepta Therapeutics Announces Research Agreement with U.S. Department of Defense to Evaluate Multiple Constructs From its Proprietary RNA Platform as Treatments for COVID-19
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

CRISPR Therapeutics and ViaCyte Announce Strategic Collaboration to Develop Gene-Edited Stem Cell-Derived Therapy for Diabetes

- Aims to develop an immune-evasive stem cell therapy as a potentially curative treatment ...

author_avatar
NASDAQ Market News

EMA Approves New Storage Option for Pfizer-BioNTech Vaccine, Easing Distribution and Storage of Doses Across European Union

author_avatar
NASDAQ Market News

Inivata and Gustave Roussy Publish Positive Results from Prospective Clinical Study in use of ctDNA Liquid Biopsy to Guide Cancer Treatment

Inivata and Gustave Roussy Publish Positive Results from Prospective Clinical Study in use of ...

author_avatar
NASDAQ Market News